INO Inovio Pharmaceuticals Inc

Price (delayed)

$2.11

Market cap

$483.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.54

Enterprise value

$457.91M

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO ...

Highlights
INO's revenue has dropped by 75% year-on-year and by 10% since the previous quarter
The gross profit has dropped by 75% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of INO
Market
Shares outstanding
229.04M
Market cap
$483.28M
Enterprise value
$457.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
288.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
285.71
Earnings
Revenue
$1.6M
EBIT
-$326.59M
EBITDA
-$321.56M
Free cash flow
-$225.74M
Per share
EPS
-$1.54
Free cash flow per share
-$1.03
Book value per share
$1.63
Revenue per share
$0.01
TBVPS
$1.98
Balance sheet
Total assets
$445.51M
Total liabilities
$90.43M
Debt
$33.65M
Equity
$355.09M
Working capital
$340.55M
Liquidity
Debt to equity
0.09
Current ratio
6.74
Quick ratio
6.2
Net debt/EBITDA
0.08
Margins
EBITDA margin
-20,063.7%
Gross margin
100%
Net margin
-20,485.9%
Operating margin
-19,990.9%
Efficiency
Return on assets
-63.5%
Return on equity
-76.5%
Return on invested capital
-78.5%
Return on capital employed
-84.6%
Return on sales
-20,377.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
2.43%
1 week
21.97%
1 month
16.57%
1 year
-74.24%
YTD
-57.72%
QTD
21.97%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$1.6M
Gross profit
$1.6M
Operating income
-$320.4M
Net income
-$328.33M
Gross margin
100%
Net margin
-20,485.9%
INO's operating income has shrunk by 112% YoY and by 6% QoQ
INO's revenue has dropped by 75% year-on-year and by 10% since the previous quarter
The gross profit has dropped by 75% year-on-year and by 10% since the previous quarter
INO's net income has dropped by 74% year-on-year and by 8% since the previous quarter

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.29
P/S
288.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
285.71
INO's EPS is down by 41% year-on-year and by 6% since the previous quarter
The stock's price to book (P/B) is 87% less than its 5-year quarterly average of 9.9 and 58% less than its last 4 quarters average of 3.0
The equity has contracted by 39% YoY and by 11% from the previous quarter
INO's revenue has dropped by 75% year-on-year and by 10% since the previous quarter
The P/S is 30% lower than the last 4 quarters average of 402.3 but 4.6% higher than the 5-year quarterly average of 269.1

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's return on assets has dropped by 75% year-on-year and by 19% since the previous quarter
INO's ROE has plunged by 58% YoY and by 22% from the previous quarter
The company's return on invested capital fell by 49% YoY and by 22% QoQ
INO's return on sales is down by 20% since the previous quarter

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
INO's current ratio has shrunk by 52% YoY
INO's quick ratio has dropped by 51% year-on-year
Inovio Pharmaceuticals's debt is 91% lower than its equity
The debt to equity has soared by 50% YoY and by 13% from the previous quarter
The equity has contracted by 39% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.